CellGuard - A Novel Approach for Protecting Cells During Bioprocessing

CellGuard - 生物加工过程中保护细胞的新方法

• 批准号: 7671200
• 负责人: John M BAUST
• 金额: $ 30.03万
• 依托单位: CELL PRESERVATION SERVICES, INC.
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7671200
• 关键词: Adjuvant; Affect; Age; Apoptosis; Area; Biological Assay; Biological Preservation; Biological Process; Biological Sciences; Biology; Bioreactors; Biotechnology; Boxing; Cell Culture Techniques; Cell Death; Cell Line; Cell Survival; Cell Therapy; Cell physiology; Cells; Cellular Stress; Cessation of life; Cocos; Complement 3a; Cryopreservation; Cryosurgery; Culture Media; Cytoprotection; Development; Devices; Dissociation; Engineering; Environment; Event; Flow Cytometry; Future; Generations; Goals; Hepatocyte; Human; Hypersensitivity; Hypoxia; In Vitro; Individual; Inhibition of Apoptosis; Investigation; Knowledge; LNCaP; Lead; Life; Link; Liver; Longevity; Maintenance; Malignant neoplasm of prostate; Marketing; Medicine; Methods; Microarray Analysis; Molecular; Molecular Analysis; Molecular Biology; Names; Necrosis; Nutrient; Pathway interactions; Performance; Personal Communication; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Phase I Clinical Trials; Phase II Clinical Trials; Procedures; Process; Production; Protocols documentation; Reporting; Research; Research Project Grants; Sampling; Science; Scientist; Series; Services; Small Business Innovation Research Grant; Solutions; Stress; System; Technology; Temperature; Testing; Thinking; Time; Tissue Engineering; Tissues; Western Blotting; Work; analog; base; biological adaptation to stress; bioprocess; cancer cell; cancer therapy; cell growth; cell type; deprivation; design; drug discovery; experience; hypothermosol; improved; innovation; insight; interest; member; new technology; novel; novel strategies; prevent; programs; public health relevance; response; tissue culture

DESCRIPTION (provided by applicant): CPSI (Cell Preservation Services, Inc) is a biotechnology company dedicated to developing novel technologies in the area of cell-molecular biology and medicine. CPSI's core molecular strategy is focused on understanding and manipulating the cell survival and death pathways that appear to be cell-specific and are activated as a consequence of cell manipulation. CPSI's knowledge of these stress pathways has led to insight into the development of a series of future products designed to improve cell bioprocessing. The goal of this research project is to develop the first generation of CellGuardTM, tissue culture additives designed to mitigate cell response to the continually changing environment a cell is exposed to during a bioprocessing procedure. The objective of CellGuardTM is to provide for a more stable culture environment thereby extending the usable interval of cells in vitro while maintaining cell performance within a standard, predictable response window. To this end, CPSI has identified a unique class of compounds, FR-48, that has shown promise. As such, these compounds offer great potential to support CPSI's cell processing program. The intent of this proposal is to (1) better understand the cell stress pathway targeted by FR-48, (2) evaluate FR-48 analogues to assess their efficacy and (3) investigate the utilization of FR-48 analogs in a pre-, intra, and post-manipulation exposure setting. Samples will be evaluated under three distinct environmental stress regimes including hypoxia, nutrient deprivation, and cell growth/aging. Phase 1 studies will utilize the HepG2/C3A liver cell line and primary hepatocytes. Phase 2 studies will be expanded to additional cell types and more in- depth analogue and cell function analysis. Investigations under this Phase 1 will include molecular analysis of FR-48's action using fluorescent assays, flow cytometry, microarray analysis, western blotting, etc. Successful completion of the project will lead to improved protocols for the active, bulk cell culture (bioprocessing) of human hepatocytes as well as other cell systems. Phase 2 studies will focus on the further development and application of the CellGuardTM product line to improve bioprocessing applications for an array of cell systems. PUBLIC HEALTH RELEVANCE: This project is designed to develop an improved series of solutions and protocols for protecting human cells during bioprocessing. This novel approach, collectively called CellGuardTM, will result in the improved viability and function of human cells such as liver cells. This, in turn, will improve the quality of future cell-based, pharmaceutical drugs as well as positively affect the use of human cells in cell therapy.

描述（由申请人提供）：CPSI（Cell Preservation Services，Inc）是一家生物技术公司，致力于在细胞分子生物学和医学领域开发新技术。 CPSI的核心分子策略的重点是理解和操纵似乎是细胞特异性的细胞存活和死亡途径，并因细胞操作而被激活。 CPSI对这些压力途径的了解已使人们深入了解一系列未来产品的开发，旨在改善细胞生物处理。该研究项目的目的是开发第一代细胞guardtm，即组织培养添加剂，旨在减轻细胞对一个细胞在生物处理过程中暴露于不断变化的环境的反应。 CellGuardTM的目的是提供更稳定的培养环境，从而在体外扩展细胞的可用间隔，同时将细胞性能保持在标准，可预测的响应窗口内。为此，CPSI已经确定了一类独特的化合物FR-48，该化合物已显示出希望。因此，这些化合物为支持CPSI的细胞处理程序提供了巨大的潜力。该提案的目的是（1）更好地了解FR-48靶向的细胞应激途径，（2）评估FR-48类似物来评估其疗效，（3）研究在Pre-pre-tr-48类似物中的利用率，内部和操作后暴露设置。样品将在三种不同的环境压力状态下进行评估，包括缺氧，营养剥夺和细胞生长/衰老。第1阶段的研究将利用HEPG2/C3A肝细胞系和原发性肝细胞。第2阶段的研究将扩展到其他细胞类型和更多深度类似物和细胞功能分析。该阶段1下的研究将包括使用荧光测定，流式细胞仪，微阵列分析，蛋白质印迹等对FR-48的作用进行分子分析。项目的成功完成将导致改善主动，大量细胞培养（生物处理）的方案。人肝细胞以及其他细胞系统。第2阶段的研究将集中于CellGuardTM产品线的进一步开发和应用，以改善针对一系列细胞系统的生物处理应用。公共卫生相关性：该项目旨在开发一系列改进的解决方案和协议，以保护生物处理过程中的人类细胞。这种新颖的方法统称为CellGuardTM，将导致人类细胞（如肝细胞）的生存能力和功能提高。反过来，这将提高未来基于细胞的药物的质量，并积极影响人类细胞在细胞疗法中的使用。